Convergent Therapeutics Appoints Radiopharmaceutical Industry Veteran Michael Rossi to its Board of Directors

AI Briefing

• – Convergent Therapeutics appoints Michael Rossi to its Board of Directors.
• – Rossi brings 30+ years of experience in radiopharmaceuticals and drug development.
• – CONV01-α completes Phase 2 study for prostate cancer treatment.